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LETTERS TO THE EDITOR
Regarding “Comparison of treatment
strategies for thoracic endograft infection”
Moulakakis et a11 recently reported an interesting meta-
analysis of infection after thoracic endovascular aortic repair
treated with preservation of the endograft or surgical excision
of the stent graft. They consider that compared with antibiotic
therapy alone, antibiotic therapy, followed by drainage and
repair of the ﬁstula, may control the sepsis, providing a tempo-
rary beneﬁt. Endograft explantation remains the gold standard
of treatment.
We fully agree that conservative, nonsurgical therapy results
invariably in a fatal outcome owing to massive hematemesis or
hemoptysis or chronic mediastinitis. A radical surgical approach
combining excision all infected tissues, in situ replacement of
the thoracic aorta, and concomitant resection of involved pul-
monary segments or the esophagus provides the most adequate
approach from a microbiologic point of view. However, despite
signiﬁcant reﬁnement in surgical techniques, the 1-year mortal-
ity of these complications after thoracic endovascular aortic
repair reported by Moulakakis et al remains considerably high:
36.6%.
First, we believe that outcomes of this devastating pathology
should be analyzed separately according to the presenting pathol-
ogy.2 Outcomes of thoracic stent graft infections are radically
different in the case of an aortobronchial or an aortoesophageal
ﬁstula.3,4
Second, in case of an aortobronchial ﬁstula, we believe that a
third way could be considered to decrease the postoperative mor-
tality in these high-risk patients. We believe that the stent graft
should be left in place and that the bronchial ﬁstula should be
addressed. Direct contact between the stent graft and the pulmo-
nary tissue should be avoided to prevent further erosive damage.
The concomitant repair may entail aortic debridement, primary
repair, or resection of the lung with coverage of the stent graft
using muscle or pleural ﬂaps. This minimally invasive approach
was performed in ﬁve of our patients, and all of them are alive af-
ter a mean follow-up of 23.2 months.5 Clearly, any strategy in
this patient population needs to be highly individualized given
the risks of major thoracic aortic surgery, often in a hostile oper-
ative ﬁeld.
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Reply
We appreciate Canaud et al for their valuable comments
on our article.1 Our study concluded that treatment of infection
after thoracic endovascular aortic repair (TEVAR) with endograft
preservation seems not a durable and perspective option.1
Although our results failed to reach statistical signiﬁcance, we
observed a trend toward a dismal outcome in overall mortality of
ﬁstula patients compared with nonﬁstula patients.
With regard to differences in outcome among patients with
aortoesophageal ﬁstula (AEF) and aortobronchial ﬁstula (ABF),
we provided separate outcomes for AEF and ABF patients.1 In
particular, ﬁve of the six patients with ABF, 21 of the 25 patients
with AEF, and all four of the patients with concomitant AEF and
ABF treated with endograft preservation died. Our study detected
a trend of a better outcome for patients treated with antibiotic
therapy, followed by additional procedures, compared with pa-
tients treated with antibiotic therapy alone. However, no further
comparison between ABF and AEF patients could be performed
because of the small patient sample.
Several authors have suggested TEVAR for rapid control of
bleeding in the setting of AEF or ABF, followed by repair of the
esophageal or bronchial defect.2,3 We congratulate Canaud
et al4 for their excellent results with this less invasive approach.
However, we must underline that their study refers to three pa-
tients with primary ﬁstulas and two with secondary. Actually,
one patient treated for an ABF after TEVAR was readmitted
4 months later due to severe mediastinitis associated with
endograft infection. Endograft explantation and silver-coated
graft replacement of the descending thoracic aorta were
performed.
Primary ﬁstulas pose the risk of acute exsanguination. Second-
ary ﬁstulas may have a more devastating outcome because the
infected endograft additionally promotes the continuous contami-
nation of blood circulation with microorganisms.5 Therefore, we
believe that the pathophysiology of the ABF should be considered
when dealing with these patients.
Similar to the strategy suggested by Canaud et al,4 Kahlberg
et al,6 in a recent study, reported a single female patient with pri-
mary ABF who underwent endovascular exclusion of the aortic
rupture, followed by lung repair and interposition of a pleural mus-
cle ﬂap between the aorta and the bronchus. She remains alive after
13 months. Lyons et al7 described a man with a secondary ABF af-
ter TEVAR who was treated with endograft preservation and lung
repair. He underwent left lower lobectomy and bovine patch inter-
position between the graft and the left upper lobe 40 months after
the index procedure, but eventually died of pleural sepsis and
recurrence of hemoptysis.7
In summary, it seems that a minimally invasive approach in
case of a ABF, as suggested by Canaud et al, consisting of aortic
debridement, primary repair, or resection of the lung with
coverage of the endograft using muscle or pleural ﬂaps, is a prom-
ising option in patients unﬁt for endograft explantation. However,
this option also carries a risk for late ﬁstula recurrence,4,7 and
further evidence is needed to conﬁrm its long-term efﬁcacy.
Finally, we agree with the suggestion that any strategy in this pa-
tient population should be highly individualized.
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